After the pandemic: perspectives on the future trajectory of COVID-19
Amalio TelentiDepartment of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, USA. [email protected]Ann M. ArvinVir Biotechnology, San Francisco, CA, USA. [email protected]Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. [email protected]Davide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. [email protected]Michael DiamondDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA. [email protected]Adolfo Garcı́a-SastreDepartment of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected]Robert F. GarryDepartment of Microbiology and Immunology, Tulane University, New Orleans, LA, USA. [email protected]Edward C. HolmesMarie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and Environmental Sciences and School of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia. [email protected]Phillip S. PangVir Biotechnology, San Francisco, CA, USA. [email protected]Herbert W. VirginDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA. [email protected]
2021en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0